KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Acadia Pharmaceuticals (ACAD) Other Operating Expenses: 2009-2025

Historic Other Operating Expenses for Acadia Pharmaceuticals (ACAD) over the last 11 years, with Sep 2025 value amounting to $21.6 million.

  • Acadia Pharmaceuticals' Other Operating Expenses rose 14.80% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.9 million, marking a year-over-year decrease of 179.48%. This contributed to the annual value of $146.5 million for FY2024, which is 251.88% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' Other Operating Expenses stood at $21.6 million, which was up 4.40% from $20.7 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Operating Expenses peaked at $23.0 million during Q1 2024, and registered a low of -$124.7 million during Q4 2024.
  • Its 3-year average for Other Operating Expenses is $3.6 million, with a median of $18.2 million in 2024.
  • Examining YoY changes over the last 5 years, Acadia Pharmaceuticals' Other Operating Expenses showed a top increase of 1,276.78% in 2024 and a maximum decrease of 797.07% in 2024.
  • Over the past 5 years, Acadia Pharmaceuticals' Other Operating Expenses (Quarterly) stood at $2.6 million in 2021, then fell by 5.78% to $2.4 million in 2022, then spiked by 641.44% to $17.9 million in 2023, then tumbled by 797.07% to -$124.7 million in 2024, then grew by 14.80% to $21.6 million in 2025.
  • Its last three reported values are $21.6 million in Q3 2025, $20.7 million for Q2 2025, and $20.4 million during Q1 2025.